Dizal has been pursuing approvals from the FDA and China’s Center for Drug Evaluation (CDE) for a new indication for Zegfrovy, as a first-line treatment for NSCLC with exon 20 insertion EGFR mutations. The post AstraZeneca Licenses Global Rights to Dizal Lung Cancer Drug for Up-to-$1.5B appeared first on GEN – Genetic Engineering and Biotechnology News.
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.